Health & Medicine

STAT+: Pharmalittle: We're reading about pancreatic and lung cancer drugs, China biotech growth, and more

28 sec read7 views0 listens

Revolution Medicines presented positive clinical trial data for daraxonrasib, a pancreatic cancer treatment, showing a significant survival benefit over standard chemotherapy. This development highlights the potential of targeted therapies in oncology and underscores the importance of ongoing research in advanced cancer treatments. Additionally, ASCO's inclusion of a Chinese-led clinical trial as a keynote presentation signals China’s growing influence in global drug development, challenging traditional pharmaceutical powerhouses.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

Illuminating the Drug Development Path with Cell-Based Reporter Assays

Cell-based reporter assays are transforming biologics development by providing sensitive, quantitative measurements of pathway activation in intact cells across discovery and clinical validation. For developers and tech professionals, these luciferas...

Ali Nemati

Biotech & Pharma8 hours ago31 sec read

Corning Advances the Organoid Revolution

Corning Life Sciences is scaling the adoption of organoids by providing specialized reagents and automated protocols that address critical barriers in standardization and reproducibility. These advancements allow biotech developers to leverage human-...

Ali Nemati

Health & MedicineMay 727 sec read

STAT+: Pharmalittle: We're reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more

Sanofi requested the FDA withdraw its type 1 diabetes drug, teplizumab, from a new expedited review program after disagreement over its approval. This highlights the tension between political influence and scientific decision-making in drug approvals...

Ali Nemati

Health & MedicineMay 128 sec read

'Forever chemicals' in baby formula? Scientists unpack FDA results

The FDA's testing of 312 infant formula samples revealed the presence of PFAS, or "forever chemicals," with PFOS detected in half of all samples. This finding is significant for developers and tech professionals as it highlights the need for advancem...

Ali Nemati

Biotech & PharmaApr 3025 sec read

STAT+: Katherine Szarama named acting director of FDA's vaccines and biologics center

Katherine Szarama has been named acting director of the FDA's Center for Biologics Evaluation and Research, overseeing vaccines, gene therapies, and blood supply regulations. This shift is crucial for developers as it may influence regulatory approac...

Ali Nemati

STAT+: Pharmalittle: We're reading about pancreatic and lung cancer drugs, China biotech growth, and more

Related Articles

Illuminating the Drug Development Path with Cell-Based Reporter Assays

Corning Advances the Organoid Revolution

STAT+: Pharmalittle: We're reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more

'Forever chemicals' in baby formula? Scientists unpack FDA results

STAT+: Katherine Szarama named acting director of FDA's vaccines and biologics center